1 Estey E. Acute myeloid leukemia: 2016 Update on risk-stratification and management[Z]. 2016:91, 824-846. 2 Blum S, Martins F, Lubbert M. Immunotherapy in adult acute leukemia[J]. Leuk Res,2017,60:63-73. 3 Lichtenegger F S, Krupka C, Haubner S, et al. Recent developments in immunotherapy of acute myeloid leukemia[J]. J Hematol Oncol,2017,10(1):142. 4 Romaniuk W,Oldziej A E,Zinczuk J,et al. [Proteasome inhibitors in cancer therapy][J]. Postepy Hig Med Dosw (Online), 2015,69:1443-1450. 5 Xu L,Luo J,Jin R,et al. Bortezomib Inhibits Giant Cell Tumor of Bone through Induction of Cell Apoptosis and Inhibition of Osteoclast Recruitment, Giant Cell Formation, and Bone Resorption[J]. Mol Cancer Ther, 2016,15(5):854-865. 6 Terwijn M,Zeijlemaker W,Kelder A,et al. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia[J]. PLoS One, 2014,9(9):e107587. 7 Wouters R,Cucchi D,Kaspers G J,et al. Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design[J]. Expert Rev Hematol, 2014,7(6):791-805. 8 张翠萍,魏辉,王慧君,等. 初诊急性髓系白血病骨髓CD34~+ CD38~-细胞群比例是初次诱导缓解率的预后因素[J]. 中国实验血液学杂志,2011,19(5):1268-1272. 9 Witte K E,Ahlers J,Schafer I,et al. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia[J]. Pediatr Hematol Oncol,2011,28(2):91-99. 10 Obeid M,Tesniere A,Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death[J]. Nat Med,2007,13(1):54-61. 11 Loke J,Khan J N,Wilson J S,et al. Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia[J]. Ann Hematol,2015,94(3):361-373. 12 Kantarjian H M,Shah N P,Cortes J E, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia[J]. Blood,2015,119(5):1123. 13 Janakiram M, Pareek V,Cheng H, et al. Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies[J]. Immunotherapy,2016,8(7):809-819. 14 Zhang Q,Liu X,Wang X B,et al. [Amplification Ex Vivo and Cytocidal Activity of Leukemia Tumor-Associated Antigen-Specific Cytotoxic T Lymphocytes][J]. 中国实验血液学杂志,2015,23(3):814-820. 15 Srivastava,Shivani,Riddell,et al. Engineering CAR-T Cells: Design Concepts.[J]. Trends in Immunol, 2015,36(8):494. |